Die diabetische Zystopathie - eine Standort-bestimmung - Wissenschaftlicher Kenntnisstand noch immer überraschend unscharf

Der wissenschaftliche Kenntnisstand über die diabetische Zystopathie ist in Anbetracht der Prävalenz und volkswirtschaftlichen Bedeutung dieser Folgeerkrankung eines Diabetes mellitus immer noch überraschend unscharf. Zeichen einer diabetischen Blasenstörung entwickelt nahezu jeder zweite Diabetiker - abhängig von der Latenz des Diabetes mellitus. Sowohl die Entwicklung einer überaktiven Blase als auch einer hypokontraktilen Blase ist möglich. Die zugrunde liegenden pathophysiologischen Vorgänge betreffen die Eigenschaften der Detrusormuskulatur unter den Bedingungen oxidativen Stresses, die cholinerge, purinerge und endothelinrezeptorvermittelte Innervation, die muskarinergen Rezeptorsubtypen, Stickoxid als Mediator, die Natriumpumpe, Prostaglandine, den „nerve growth factor” (NGF) und andere Faktoren. Therapeutische Ansätze für eine gezielte Therapie der diabetischen Zystopathie sind rar und im Experimentalstadium. Während - wie für alle Diabetes-Folgeerkrankungen bewiesen - eine optimale Blutzuckereinstellung günstige Effekte hinsichtlich der Progredienz der Erkrankung zu zeigen scheint, liegen lediglich tierexperimentelle Untersuchungen zum Beispiel über gentechnische Ansätze zur Substitution des „nerve growth factors” vor.

The knowledge of the diabetic cystopathy in relation to the prevalence and cost of the health care system are still unclear. Every second patient with diabetes mellitus develops signs of diabetic urinary bladder symptoms. Both the symptoms of over- and hypo-activity are possibly based on pathological changes which are based on different levels: they influence the smooth muscle of the detrusor in situations of oxidative stress, cholinergic, purineric innervations through the receptors of the endothelium, muscarinic sub-receptors, NOS as a mediator, sodium pump, prostaglandine, nerve growth factor (NGF), and other factors. There are very few therapeutic approaches that target the treatment of diabetic cystopathy. Whereas with experimental, as with all other diabetic side effects, optimum blood sugar adjustment has the best possibility to influence to prognosis. However, only experimental genetic approaches using NGF substitution are published.

diabetes - diabetic cystopathy - lower urinary tract symptoms - urodynamics - detrusor dysfunction

Literatur

• 1 Ayan S, Kaloglu C, Gokce G. et al. . Effect of insulin therapy for diabetic cystopathy - urodynamic and histological findings in a rabbit model.  Scand J Urol Nephrol. 1999;  33 392-395
• 2 Benko R, Lazar Z, Porszasz R. et al. . Effect of experimental diabetes on cholinergic, purinergic and peptidergic motor responses of the isolated rat bladder to electrical field stimulation or capsaicin.  Eur J Pharmacol. 2003;  478 73-80
• 3 Bennett NE, Kim JH, Wolfe DP. et al. . Improvement in erectile dysfunction after neurotrophic factor gene therapy in diabetic rats.  J Urol. 2005;  173 1820-1824
• 4 Beshay E, Carrier S. Oxidative stress plays a role in diabetes-induced bladder dysfunction in a rat model.  Urology. 2004;  64 1062-1067
• 5 Changolkar AK, Hypolite JA, Disanto M. et al. . Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase.  J Urol. 2005;  173 309-313
• 6 Dahlstrand C, Dahlstrom A, Ahlman H. et al. . Effect of substance P on detrusor muscle in rats with diabetic cystopathy.  Br J Urol. 1992;  70 390-394
• 7 Frimodt-Moller C. Diabetic cystopathy: epidemiology and related disorders.  Ann Intern Med. 1980;  92 318-321
• 8 Goins WF, Yoshimura N, Phelan MW. et al. . Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: potential treatment for diabetic bladder dysfunction.  J Urol. 2001;  165 1748-1754
• 9 Gupta S, Wein AJ. Role of Na(+)-K(+)-ATPase activity in regulation of detrusor contractility and diabetic bladder dysfunction.  Adv Exp Med Biol. 1999;  462 293-302
• 10 Ichiyanagi N, Tsujii T, Masuda H. et al. . Changed responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: possible role of 5-hydroxytryptamine for diabetic bladder dysfunction.  J Urol. 2002;  168 303-307
• 11 Ishigooka M, Hashimoto T, Hayami S. et al. . Thermoreceptor mediated bladder sensation in patients with diabetic cystopathy.  Int Urol Nephrol. 1997;  29 551-555
• 12 Kaplan SA, Te AE, Blaivas JG. Urodynamic findings in patients with diabetic cystopathy.  J Urol. 1995;  153 342-344
• 13 Karicheti V, Santizo C, Zhao W. et al. . Changes in electrical properties of detrusor smooth muscle in the STZ (streptozotocin)-diabetic rat.  Urology. 2001;  57 110-111
• 14 Kodama M, Takimoto Y. Influence of 5-hydroxytryptamine and the effect of a new serotonin receptor antagonist (sarpogrelate) on detrusor smooth muscle of streptozotocin-induced diabetes mellitus in the rat.  Int J Urol. 2000;  7 231-235
• 15 Lifford KL, Curhan GC, Hu FB. et al. . Type 2 diabetes mellitus and risk of developing urinary incontinence.  J Am Geriatr Soc. 2005;  53 1851-1857
• 16 Miyamae K, Yoshida M, Inadome A. et al. . Acetylcholine release from urinary bladder smooth muscles of non-insulin-dependent diabetic rats.  Urol Int. 2004;  73 74-80
• 17 Mumtaz FH, Dashwood MR, Thompson CS. et al. . Increased expression of endothelin B receptors in the diabetic rabbit urinary bladder: functional relevance.  BJU Int. 1999;  83 113-122
• 18 Mumtaz FH, Lau DH, Siddiqui EJ. et al. . Changes in cholinergic and purinergic neurotransmission in the diabetic rabbit bladder.  In Vivo. 2006;  20 1-4
• 19 Mumtaz FH, Sullivan ME, Thompson CS. et al. . Alterations in the nitric oxide synthase binding sites and non-adrenergic, non-cholinergic mediated smooth muscle relaxation in the diabetic rabbit bladder outlet: possible relevance to the pathogenesis of diabetic cystopathy.  J Urol. 1999;  162 558-566
• 20 Mumtaz FH, Thompson CS, Khan MA. et al. . Alterations in the formation of cyclic nucleotides and prostaglandins in the lower urinary tract of the diabetic rabbit.  Urol Res. 1999;  27 470-475
• 21 Pinna C, Zanardo R, Puglisi L. Prostaglandin-release impairment in the bladder epithelium of streptozotocin-induced diabetic rats.  Eur J Pharmacol. 2000;  388 267-273
• 22 Rapidi CA, Karandreas N, Katsifotis C. et al. . A combined urodynamic and electrophysiological study of diabetic cystopathy.  Neurourol Urodyn. 2006;  25 32-38
• 23 Sasaki K, Chancellor MB, Phelan MW. et al. . Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root ganglia.  J Urol. 2002;  168 1259-1264
• 24 Sasaki K, Yoshimura N, Chancellor MB. Implications of diabetes mellitus in urology.  Urol Clin North Am. 2003;  30 1-12
• 25 Soylu A, Akinci A, Yilmaz U. et al. . Sympathetic skin responses in type-1-diabetic children: relationship to urodynamic findings.  Neurourol Urodyn. 2006;  25 243-248
• 26 Tong YC, Cheng JT. Alteration of M(3) subtype muscarinic receptors in the diabetic rat urinary bladder.  Pharmacology. 2002;  64 148-151
• 27 Tong YC, Chin WT, Cheng JT. Alterations in urinary bladder M2-muscarinic receptor protein and mRNA in 2-week streptozotocin-induced diabetic rats.  Neurosci Lett. 1999;  277 173-176
• 28 Tong YC, Chin WT, Cheng JT. Role of sorbitol in the up-regulation of urinary bladder M(2) muscarinic receptors in streptozotocin-induced diabetic rats.  Neurourol Urodyn. 2002;  21 154-159
• 29 Torffvit O, Agardh CD, Mattiasson A. Lack of association between cystopathy and progression of diabetic nephropathy in insulin-dependent diabetes mellitus.  Scand J Urol Nephrol. 1997;  31 365-369
• 30 Ueda T, Yoshimura N, Yoshida O. Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response.  J Urol. 1997;  157 580-584
• 31 Van PH, Stessens R, Van DB. et al. . Diabetic cystopathy: neuropathological examination of urinary bladder biopsies.  Eur Urol. 1988;  15 128-131
• 32 Watanabe T, Miyagawa I. Effects of long-chain fatty alcohol on peripheral nerve conduction and bladder function in diabetic rats.  Life Sci. 2002;  70 2215-2224
• 33 Ziegler D. Diagnosis and treatment of diabetic autonomic neuropathy.  Curr Diab Rep. 2001;  1 216-227

Korrespondenz